Clinical CEST MRI Fingerprinting to Track Brain Metastasis Treatment Response
Official title: Development of a Clinical CEST MR Fingerprinting Method for Treatment Response Assessment in Brain Metastases
Funded at Sloan-Kettering Inst Can Research · NIH-11384800 · Data updated 2026-11-12
A patient-facing overview of a new MRI method that uses advanced imaging and AI to measure how brain metastases respond to treatment.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | April 1, 2022 |
| Project end | July 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $693,184 |
| NIH project number | 5R37CA262662-05 |
| Project ID | NIH-11384800 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with brain metastases undergoing treatment and scheduled for MRI follow-up.
✕Less likely to help
Patients not receiving MRI-based monitoring or those not eligible for CEST imaging may not benefit.
What this research studies
This grant supports developing a faster, quantitative CEST MRI fingerprinting technique to measure tumor chemistry and microenvironment changes during treatment. The approach aims to produce maps of proton exchange rates and protein/metabolite concentrations that relate to how tumors respond. By reducing scan time and improving data processing, the method could make brain metastasis imaging more informative and easier to use in clinical care.
Why it matters
Potential benefit: If successful, patients with brain metastases could receive clearer, quicker assessments of how their tumors respond to therapy.
How similar studies have gone: Previous CEST-MRI studies showed promise in distinguishing treatment effects, with translational progress hampered by technical hurdles; this project addresses those gaps.
Where this research is happening
-
Sloan-Kettering Inst Can Research
New York, United States Active
Researchers
- Principal investigator: Cohen, Ouri — Sloan-Kettering Inst Can Research
- Study coordinator: Cohen, Ouri
Related research
Other NIH-funded projects on the same topics.
-
Understanding and interrupting brain metastasis in cancer patients
A national research effort at Stanford aims to understand why cancer spreads to the brain and to develop ways to interrupt it, with the goal of improving survival and quality of life for people with cancer.
-
Rational approaches to improve treatment for breast cancer that has spread to the brain
Aimed at boosting how well a HER2-targeted antibody-drug conjugate works for people whose breast cancer has spread to the brain.
-
Understanding how brain metastasis in triple-negative breast cancer is shaped by tumor-immune interactions
A patient-focused program aims to learn why TNBC spreads to the brain and how the immune system interacts with those cancer cells, with a focus on women of African ancestry.
-
AI-driven automatic treatment planning for brain metastases radiotherapy
A new AI-based system helps plan precise stereotactic radiosurgery for people with multiple brain metastases.
-
Endocrine therapy and radiation work together to reduce brain metastases
Aims to understand how hormone therapy and radiation together help the body fight breast cancer that has spread to the brain, especially in younger women.
-
Personalized brain metastases risk map to guide radiotherapy
A new approach uses personal MRI data to predict where brain metastases might develop so radiation can target high-risk areas and spare healthy brain tissue.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.